BACKGROUND The cellular prion protein(PrPC),traditionally associated with neurodegenerative disorders,plays an important role in cancer progression and metastasis by inhibiting apoptosis.AIM To investigate the influen...BACKGROUND The cellular prion protein(PrPC),traditionally associated with neurodegenerative disorders,plays an important role in cancer progression and metastasis by inhibiting apoptosis.AIM To investigate the influence of PrPC expression in cholangiocarcinoma(CCA)on patient outcomes following surgical resection.METHODS Patients who underwent curative surgical resection for either intrahepatic or hilar CCA were enrolled in this retrospective study.Based on the immunohistochemical staining results of the surgical specimens,patients were categorized into two groups:The low PrPC group(negative or 1+)and the high PrPC group(2+or 3+).Survival analyses,including overall survival and recurrence-free survival,were conducted using the Kaplan-Meier method and compared using the log-rank test.RESULTS In total,seventy-six patients diagnosed with CCA(39 with intrahepatic and 37 with hilar CCA)underwent curative hepatectomy from January 2011 to November 2021.Among these patients,38(50%)demonstrated high PrPC expression,whereas the remaining 38(50%)showed low expression of PrPC.During a median follow-up period of 31.2 months(range:1 to 137 months),the high PrPC group had a significantly shorter median overall survival than the low PrPC group(40.4 months vs 137.9 months,respectively;P=0.041).Moreover,the high PrPC group had a significantly shorter median recurrence-free survival than the low PrPC group(13.3 months vs 23.8 months,respectively;P=0.026).CONCLUSION PrPC expression is significantly associated with early recurrence and decreased survival period in CCA patients following surgical resection.Thus,PrPC may be used as a prognostic factor in treatment planning.展开更多
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death and has a poor prognosis with a 5-year survival rate of 9%. In 2019, 56,770 new PDAs and 45,750 deaths are projected to occur ...Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death and has a poor prognosis with a 5-year survival rate of 9%. In 2019, 56,770 new PDAs and 45,750 deaths are projected to occur in the United States (1). Because of the dismal prognosis, it is important to predict the course of the disease precisely. The TNM staging system is a widely used not only for predicting prognosis but also for collecting and exchanging cancer information. The American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition was introduced in October 2016 and there were many changes in the staging of PDA compared with the previous one. Of the several controversies related with the previous edition, the most important one was the reproducibility of the T-category. In the 7th edition, there were discrepancies in opinion among pathologists about pT3 (extension beyond the pancreas). Because the pancreas does not have a capsule, it is difficult to determine if there is an extra-pancreatic extension in the presence of inflammation or desmoplasia. Therefore, in the revised staging system, T-category was classified by size, regardless of the extra-pancreatic invasion: pT1, ≤2 cm in maximal diameter;pT2,>2 cm but ≤4 cm;pT3, >4 cm;pT4, locally unresectable due to involvement of major arteries (the celiac axis or the superior mesenteric artery). Another controversy in the 7th edition was that the N-category is simply divided into pN0 and pN1. It has been suggested that the N-category should be subdivided because the number of metastatic lymph nodes (LNs) affects prognosis (2).展开更多
基金Supported by National Research Foundation of Korea Grant Funded by the Korea Government,No.RS-2023-00213951.
文摘BACKGROUND The cellular prion protein(PrPC),traditionally associated with neurodegenerative disorders,plays an important role in cancer progression and metastasis by inhibiting apoptosis.AIM To investigate the influence of PrPC expression in cholangiocarcinoma(CCA)on patient outcomes following surgical resection.METHODS Patients who underwent curative surgical resection for either intrahepatic or hilar CCA were enrolled in this retrospective study.Based on the immunohistochemical staining results of the surgical specimens,patients were categorized into two groups:The low PrPC group(negative or 1+)and the high PrPC group(2+or 3+).Survival analyses,including overall survival and recurrence-free survival,were conducted using the Kaplan-Meier method and compared using the log-rank test.RESULTS In total,seventy-six patients diagnosed with CCA(39 with intrahepatic and 37 with hilar CCA)underwent curative hepatectomy from January 2011 to November 2021.Among these patients,38(50%)demonstrated high PrPC expression,whereas the remaining 38(50%)showed low expression of PrPC.During a median follow-up period of 31.2 months(range:1 to 137 months),the high PrPC group had a significantly shorter median overall survival than the low PrPC group(40.4 months vs 137.9 months,respectively;P=0.041).Moreover,the high PrPC group had a significantly shorter median recurrence-free survival than the low PrPC group(13.3 months vs 23.8 months,respectively;P=0.026).CONCLUSION PrPC expression is significantly associated with early recurrence and decreased survival period in CCA patients following surgical resection.Thus,PrPC may be used as a prognostic factor in treatment planning.
文摘Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death and has a poor prognosis with a 5-year survival rate of 9%. In 2019, 56,770 new PDAs and 45,750 deaths are projected to occur in the United States (1). Because of the dismal prognosis, it is important to predict the course of the disease precisely. The TNM staging system is a widely used not only for predicting prognosis but also for collecting and exchanging cancer information. The American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edition was introduced in October 2016 and there were many changes in the staging of PDA compared with the previous one. Of the several controversies related with the previous edition, the most important one was the reproducibility of the T-category. In the 7th edition, there were discrepancies in opinion among pathologists about pT3 (extension beyond the pancreas). Because the pancreas does not have a capsule, it is difficult to determine if there is an extra-pancreatic extension in the presence of inflammation or desmoplasia. Therefore, in the revised staging system, T-category was classified by size, regardless of the extra-pancreatic invasion: pT1, ≤2 cm in maximal diameter;pT2,>2 cm but ≤4 cm;pT3, >4 cm;pT4, locally unresectable due to involvement of major arteries (the celiac axis or the superior mesenteric artery). Another controversy in the 7th edition was that the N-category is simply divided into pN0 and pN1. It has been suggested that the N-category should be subdivided because the number of metastatic lymph nodes (LNs) affects prognosis (2).
